Drugs / TETA 4HCL
TETA 4HCL
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07465718 | Jul 2026 → Feb 2028 expected | Wilson disease | Orphalan | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT03539952 | Sep 2018 → Aug 2020 | Wilson disease | Orphalan | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TETA 4HCl | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07465718 ↗ |
| Known as | TETA4 | “We aimed to compare penicillamine with trientine tetrahydrochloride (TETA4) for maintenance therapy in patients with Wilson disease.” PMID 36183738 ↗ Sep 2022 |
| Known as | trientine tetrahydrochloride | “A new formulation of trientine tetrahydrochloride (TETA 4HCl) has been developed to be administered once a day.” NCT07465718 ↗ |
| Route | Oral | “switched mg-for-mg to oral TETA4” PMID 36183738 ↗ Sep 2022 |